Xyloglucan based mucosal nanovaccine for immunological protection against brucellosis developed by supercritical fluid technology

Vyas, Swati; Dhoble, Sagar; Ghodake, Vinod; Patravale, Vandana

doi:10.1016/j.ijpx.2020.100053

Cited by 9 publications

(7 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, the inclusion of xyloglucan in the formulation led to a significant decrease in sIgA levels in the pulmonary mucus. A recent independent study showed that a nanovaccine containing Quillaja saponin and Brucella abortus S19 LPS elicited a mixed Th1/Th2 type of immunity in BALB/C mice when administered intranasally [ 27 ]. However, the study found a stronger IgG2a response than IgG1, which differed from the findings in the current study.…”

Section: Discussionmentioning

confidence: 99%

“…The Brucella smooth LPS is several hundred times less toxic and non-pyrogenic compared to other lipopolysaccharides [ 24 ], making it a potential alternative vaccine. Its utility in protecting against brucellosis has been demonstrated [ 24 , 25 , 26 , 27 ]. Xyloglucan is a natural plant polysaccharide and non-toxic food additive with mucoadhesive and immunopotentiation properties [ 28 , 29 , 30 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Safe Subunit Green Vaccines Confer Robust Immunity and Protection against Mucosal Brucella Infection in Mice

et al. 2023

View full text Add to dashboard Cite

Brucellosis is a zoonotic disease that causes significant negative impacts on the animal industry and affects over half a million people worldwide every year. The limited safety and efficacy of current animal brucellosis vaccines, combined with the lack of a licensed human brucellosis vaccine, have led researchers to search for new vaccine strategies to combat the disease. To this end, the present research aimed to evaluate the safety and efficacy of a green vaccine candidate that combines Brucella abortus S19 smooth lipopolysaccharide (sLPS) with Quillaja saponin (QS) or QS-Xyloglucan mix (QS-X) against mucosal brucellosis in BALB/C mice. The results of the study indicate that administering two doses of either sLPS-QS or sLPS-QS-X was safe for the animals, triggered a robust immune response, and enhanced protection following intranasal challenge with S19. Specifically, the vaccine combinations led to the secretion of IgA and IgG1 in the BALF of the immunized mice. We also found a mixed IgG1/IgG2a systemic response indicating evidence of both Th1 and Th2 activation, with a predominance of the IgG1 over the IgG2a. These candidates resulted in significant reductions in the bioburden of lung, liver, and spleen tissue compared to the PBS control group. The sLPS-QS vaccination had conferred the greatest protection, with a 130-fold reduction in Brucella burdens in lung and a 55.74-fold reduction in the spleen compared to PBS controls. Vaccination with sLPS-QS-X resulted in the highest reduction in splenic Brucella loads, with a 364.6-fold decrease in bacterial titer compared to non-vaccinated animals. The study suggests that the tested vaccine candidates are safe and effective in increasing the animals’ ability to respond to brucellosis via mucosal challenge. It also supports the use of the S19 challenge strain as a safe and cost-effective method for testing Brucella vaccine candidates under BSL-2 containment conditions.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Safe Subunit Green Vaccines Confer Robust Immunity and Protection against Mucosal Brucella Infection in Mice

et al. 2023

View full text Add to dashboard Cite

show abstract

“…While Brucella LPS was weakly immunogenic, when B. abortus LPS-loaded XG NPs were administered nasally to Balb/c mice, higher systemic and mucosal IgG antibody levels and mucosal IgA were induced. Increased immunogenicity was associated with a greater mucoadhesion force of the XG and the LPS-XG NPs compared to the LPS alone, as well as the ex vivo retention of LPS-XG NPs over 24 h in goat mucosa [ 141 ].…”

Section: Mucoadhesive and Mucopenetrating Polymer-based Adjuvantsmentioning

confidence: 99%

The Role of Mucoadhesion and Mucopenetration in the Immune Response Induced by Polymer-Based Mucosal Adjuvants

et al. 2023

View full text Add to dashboard Cite

Mucus is a viscoelastic gel that acts as a protective barrier for epithelial surfaces. The mucosal vehicles and adjuvants need to pass through the mucus layer to make drugs and vaccine delivery by mucosal routes possible. The mucoadhesion of polymer particle adjuvants significantly increases the contact time between vaccine formulations and the mucosa; then, the particles can penetrate the mucus layer and epithelium to reach mucosa-associated lymphoid tissues. This review presents the key findings that have aided in understanding mucoadhesion and mucopenetration while exploring the influence of physicochemical characteristics on mucus–polymer interactions. We describe polymer-based particles designed with mucoadhesive or mucopenetrating properties and discuss the impact of mucoadhesive polymers on local and systemic immune responses after mucosal immunization. In future research, more attention paid to the design and development of mucosal adjuvants could lead to more effective vaccines.

show abstract

“…Other examples include the use of PLGA NPs encapsulating antigens and adjuvants to treat leishmaniasis [17], a coordination polymer formed between Manganese (Mn 2+ ) and an organic ligand, meso-2,6-diaminopimelic acid, encapsulating ovalbumin for tumor therapy [18], xyloglucan (a tamarind seed-derived polymer) NPs encapsulating lipopolysaccharides from Brucella spp. as a mucosal vaccine against brucellosis that showed superior mucosal adhesive properties [19], and a peptide-polymer NP capable of transforming into nanosheets in an acidic pH, releasing the antigen to the cytoplasm for cancer therapy [20]. Different routes of administration were utilized depending on the nature of the polymeric delivery vehicle and antigenic component.…”

Section: Trends In Pharmacological Sciencesmentioning

confidence: 99%

“…Different routes of administration were utilized depending on the nature of the polymeric delivery vehicle and antigenic component. While certain vaccines elicited robust immune responses when administered intramuscularly or subcutaneously, other vaccines were more efficient when administered intranasally because they had excellent mucosal adhesive properties that promoted the activation of mucosa resident innate immune cells [15,19]. In all these examples, the use of a polymer led to either protective immunity or high levels of antibody production in vivo, showing that polymers are excellent components and carriers for vaccines.…”

Section: Trends In Pharmacological Sciencesmentioning

confidence: 99%

Biomaterials, biological molecules, and polymers in developing vaccines

Ravi

Shamiya

Chakraborty

et al. 2021

Trends in Pharmacological Sciences

View full text Add to dashboard Cite

Vaccines have been used to train the immune system to recognize pathogens, and prevent and treat diseases, such as cancer, for decades. However, there are continuing challenges in their manufacturing, large-scale production, and storage. Some of them also show suboptimal immunogenicity, requiring additional adjuvants and booster doses. As an alternate vaccination strategy, a new class of biomimetic materials with unique functionalities has emerged in recent years. Here, we explore the current bioengineering techniques that make use of hydrogels, modified polymers, cell membranes, self-assembled proteins, virus-like particles (VLPs), and nucleic acids to deliver and develop biomaterial-based vaccines. We also review design principles and key regulatory issues associated with their development. Finally, we critically assess their limitations, explore approaches to overcome these limitations, and discuss potential future applications for clinical translation. Vaccines and their limitationsSeveral prophylactic and therapeutic vaccines (see Glossary) are successfully used to protect humans against numerous infectious pathogens and diseases, and to prevent their spread among communities worldwide. According to the WHO, more than 70% of children were given shots of routinely administered vaccines (Box 1) globally in 2019 i . Efforts are continuously being made to develop new vaccines for emerging and established pathogens and diseases, the current Coronavirus 2019 (COVID-19) pandemic being a good example. The area of therapeutic vaccine development, particularly for cancer therapy, is also being widely studied [1]. With an increasing demand for high-quality vaccines, there is a need to investigate innovative and novel approaches that are superior to conventional methods (Box 1). Polymer-based nanoparticles (NPs) and nanostructured materials could aid these efforts owing to their favorable characteristics and widespread success in other fields [1][2][3][4]. These NPs can be used to address the current limitations of traditional vaccines, such as low immunogenicity, safety issues, and need for booster doses [5][6][7][8][9]. Here, we discuss different approaches used to elevate the efficacy of vaccines for multiple applications using the principles of engineering (Figure 1, key figure). Engineered biological and biomaterial vaccinesThe engineering of diverse biomaterials, organisms, and biological molecules can yield improved vaccines and vaccine delivery vehicles that overcome several, if not all, of the current limitations and challenges in the field of vaccine development [10]. The following are six approaches using polymeric hydrogels, biologically modified polymers, cell membranes, self-assembled proteins, VLPs, and nucleic acids that have been applied to advance the efficacy and competence of vaccines. The first three approaches make use of the properties of the materials to enhance the delivery of the encapsulated antigens, and the latter three exploit the properties of the biological molecules to develop superior a...

show abstract

Xyloglucan based mucosal nanovaccine for immunological protection against brucellosis developed by supercritical fluid technology

Cited by 9 publications

References 47 publications

Safe Subunit Green Vaccines Confer Robust Immunity and Protection against Mucosal Brucella Infection in Mice

Safe Subunit Green Vaccines Confer Robust Immunity and Protection against Mucosal Brucella Infection in Mice

The Role of Mucoadhesion and Mucopenetration in the Immune Response Induced by Polymer-Based Mucosal Adjuvants

Biomaterials, biological molecules, and polymers in developing vaccines

Contact Info

Product

Resources

About